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The novel compound of the disclosure is 4-chloro-4-(4ethoxy-pheny 1)-2-( fiuoren-9-y lidene-hydrazono )-but-3enoic acid methyl ester (3F-19), and it alone or in combination with 4-( 4-Ethoxy-phenyl)-2-(N'-fiuoren-9-ylidenehydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OF13), appears useful in humans as therapeutic means for the
eradication of tumors from the human's colon.
4 Claims, 1 Drawing Sheet
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which are said to inhibit tumor metastasis (column 7, line
56 and column 8, line 4);
FIELD OF THE INVENTION
Frechette (U.S. Pat. No. 5,696,117), Frechette (U.S. Pat. No.
5,854,242) and Frechette (U.S. Pat. No. 5,707,990)
This is a Divisional of application Ser. No. 10/164,879
5
describe 148 benzoxazine and pyrido-oxazine heterocyfiled Jun. 7, 2002, and this invention relates to the use of
clic as anti-bacterial compounds;
novel compounds alone or in combination or treatment of
Omedi-Sale (U.S. Pat. No. 3,862,954) shows tri-azole comhuman colon cancer and claims the benefit of priority of U.S.
pounds for CNS use;
Provisional Application Ser. No. 60/296,823 filed Jun. 8,
Hawkins (U.S. Pat. No. 5,274,002) describes many analogs
2001.
10
of phenyl ethers of a substituted phenyl of the formula
structure at column 1, lines 49-60 with 37 examples of
BACKGROUND OF THE INVENTION
specific compounds which compounds may be useful for
Cancer is a global killer of humans with breast cancer and
tumor inhibition (column 22, line 64); and,
colon cancer among the leaders with many other types
Boyd, et al (U.S. Pat. No. 6,080,790) also describes many
killing modest amounts of humans yearly. Breast cancer is 15
tri-substituted phenyl derivatives according to the formula
the primary killer of women. Colon cancer is the third
of the Abstract with 15 examples of specific compounds
greatest killer of people in the United States.
which may be useful for malignant skin diseases (column
Colon cancer although having an excellent cure rate is a
5, line 46).
very common cancer second only to lung cancer in the
It appears from a review of the foregoing patents that
United States. 129,400 new cases of colorectal cancer were 20 neither the 2-hydrazino-3-oxo-butenoic acid nor the
estimated for 1999 with 56,600 deaths therefrom. The stron2-hydroxy-4-oxobutyric acid derivatives of interest are disgest risk factor for colon cancer is age. The incidence rates
closed and thus there is no report of their activity against
rise from 10 per 100,000 at age 40-45 to 300 per 100,000 at
human colon cancer.
age 75-80. The cumulative life time risk for the disease is 1
Consequently, there is a need for an anti-cancer drug for
in 20. Men are more likely to develop colon cancer than 25 humans that mitigate the above mentioned disadvantages of
women. Black Americans are more likely than white Americurrent drug therapy and effectiveness against the identified
cans to be diagnosed with colorectal cancer. Smokers,
human colon cancer.
drinkers, sedentary, and obese persons are more likely to
develop colon cancer.
SUMMARY OF THE INVENTION
The U.S. patent literature has many disclosures of oxo- 30
butenoic ( crotonic) compounds:
The first objective of the present invention is to provide a
Pamukci (U.S. Pat. No. 6,232,312) describes crotonic acid
novel drug effective for treatment of human colon cancer.
derivatives (column 22, lines 43-58) for the treatment of
Another object of this invention is to provide a novel
colonic polyps;
2-hydrazino-3-oxo-butenoic acid derivative.
Jones et al (U.S. Pat. No. 6,121,450) discloses crotonic acid 35
A preferred embodiment of the invention encompasses the
derivatives (column 8, line 34; column 78, line 24 and at
specific compounds: 4-Chloro-4-( 4-ethoxy-phenyl)-2example 34 as steroid modifiers in treating breast cancer
(fluoren-9-ylidene-hydrazono)-but-3-enoic acid methyl
(column 1, lines 55-58);
ester (3F-19), and the use of it and/or 4-(4-Ethoxy-phenyl)Kalden, et al (U.S. Pat. No. 5,334,612) discloses compounds
said to be useful for treating AIDS including derivatives 40 2-(N' -fl uoren -9-y lidene- hydrazino )-2-h ydroxy-4-oxobutyric acid methyl ester (OF-13) in humans as therapeutic
of carboxylic acid (column 9, line 31) and pyrrolidine
means for the eradication of tumors from the human's colon.
(column 7, line 24);
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral
Further objects and advantages of this invention will be
admixture containing crotonic acid for treating tumors
apparent from the following detailed description of presently
(see Abstract);
45 preferred embodiments, which are illustrated structurally in
Harwell, et al (U.S. Pat. No. 5,580,896) discloses many
the accompanying drawings.
4-oxo-2-butenoic acid derivatives (column 13, lines
21-59; also in columns 15+, examples 25, 26, 32, 34, 40,
BRIEF DESCRIPTION OF THE FIGURES
43-46, 77-79, 97, 99, 103, 106,), which are useful for
inhibiting colorectal cancer, i.e., colon cancer (Abstract); 50
FIG. 1 illustrates structurally a chemical compound desGiordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxoignated as 3F-19.
2-butenoic acid derivatives said to be useful for treatment
FIG. 2 illustrates structurally a chemical compound desof AIDS (column 1, line 8 and column 2, line 61; and,
ignated as OF-13.
Yonemeto, et al (U.S. Pat. No. 6,083,985) recites a number
of anti-tumor or anti-AIDS agents that include butenoic 55
DESCRIPTION OF THE PREFERRED
acid derivatives.
EMBODIMENTS
The U.S. patent literature has many disclosures of

TREATMENT OF COLON CANCER

butanoic acid derivatives including:
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many
anti-inflammatory and analgesic compounds, including
adenocarcinoma (column 1, line 55), which includes
heterocyclic alcohol-esters (column 11, lines 1-16) and
butanoic acid derivatives (many Examples including 47
through 162);
Girard, et al (U.S. Pat. No. 5,308,852) discloses many
compounds including butanoic acid derivatives (see
Methods B and C of schemes II and III) which compounds

60

65

Before explaining the disclosed embodiments of the
present invention in detail, it is to be understood that the
invention is not limited in its application to the details of the
particular arrangement shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
As earlier recited this application has been filed in order
to both disclose the novel 2-hydrazino-3-oxo-butenoic acid
derivative structurally shown in FIG. 1 as well as the use of
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the structure in FIGS. 1 and/or 2 for biological activity
Preparation of OF-13
useful for the treatment of human colon cancer. More
specifically this application discloses the anti-tumor comEXAMPLE 2
pounds: 4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fluoren-9ylidene-hydrazono )-but-3-enoic acid methyl ester (3F-19); 5
and, 4-( 4-Ethoxy-phenyl) 2 -(N'-fluoren-9-ylideneThe preparation of 4( 4-Ethoxyphenyl)-2-(N'-fluoren-9hydrazino)-2-hydroxy-4-oxo-butyric acid methyl ester (OFylidene-hydrazino
)-2-hydroxy-4-oxobutyric acid methyl
13).
ester
(OF-13).
A
solution
of 5.0 g (0.02 moles) of methyl
To facilitate a fill understanding of the invention:
the compound designated as 3F-19 is 4-Chloro-4-( 4-ethoxy- 10 4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
3.88 g (0.02 moles) of fluorene-9-ylidene-hydrazine (2) in
phenyl)-2-fluoren-9-ylidene-hydrazono)but-3-enoic acid
80 mL of absolute benzene and absolute toluene (1:1) was
methyl ester; and
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of
the compound designated as OF-13 is 4-(4-Ethoxypheny1)-2-N'-fluoren-9-ylidene-hydrazino )-2-hydroxythe reaction was determined by TLC), cooled and the
15
4-oxo-butyric acid methyl ester.
precipitate was filtered and recrystallized from benzeneThese compounds have very high activity against colon
diethyl ether-hexane mixture (1:3:2) to give 2.65 g (53%
cancer and a very low toxicity as a (LD 50) in animals. The
yield) of colorless crystals with mp 114-116° C.
percent activity and animal toxicity for each compound is as
follows:
Solubility: highly soluble in DMSO, DMFA,
3F-19 (100% against human colon cancer and LD 50 >200 20
dichloroethane, acetonitrile, insoluble in hexane. The commg/kg); and,
pound is not stable in solutions and decomposes quickly
OF-13 (100% against human colon cancer and LD 50 >1500
when the solution is heated or stored for a long time with the
mg/kg).
Preparation of (3F-19)
formation of OF-12.
25

EXAMPLE 1

~COOCH3+
~, __
OH

The preparation of 4-Chloro-4( 4-ethoxy-phenyl)-2C2HsO~
(fluoren-9-ylidene-hydrazono )-but-3-enoic acid methyl
0
ester (3F-19) To the solution of 10 g (0.0026 moles) of 30
4-( 4-Ethoxy-phenyl)-2-(N'-fluoren-9-lidene-hydrazino )-4oxo-but-2-enoic acid methyl ester (1) (synthesis was previously published by Konyukhova, N. A Krasnykh, 0. P.;
Aliev, Z. G.; Maslivets, A N. Chemistry of Heterocyclic
Compounds (New York, N.Y., United States)(Translation of 35
Khimiya Geterotsiklicheskikh Soedinenii) (2001), 37(6),
779-780) in 5 mL of anhydrous benzene 0.3935 g (0.0031
moles) oxalyl chloride was added. The reaction mixture was
refluxed for 1 hour 40 min, cooled, the precipitate was
filtered and recrystallized from absolute benzene to give
0.62 g (54%) of yellow crystals, m.p. 163-163 (decamp).

2
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Matrix-solvent that the samples are prepared/diluted in
-continued
OH
Assay samples of similar origin and matrix (e.g., methanol
~COOCH3
extraction, methylene chloride extraction, water soluble
samples, etc.) together on the same plate in order to
C2HsO~
, __ _
5
reduce the number of steps performed per plate.
0
NH
Blank values will be determined for each sample to account
for any color contribution due to the sample itself. These
blank wells must contain the same amount of sample plus
CCL220 media (no cells). After completion of MTS/PMS
10
reaction blank values will be subtracted from the test
value to obtain a net absorbance that will be used to
calculate cell density.
All results are based upon a comparison to the Negative
Control value of the plate. The Negative Control must
15 contain the same amount of matrix (e.g., solvent) to offset
any destructive effect the matrix may have on the growth of
the CCL220 cells (allows for baseline values to be set).
For most samples, a CCL220 cell growth (initial density
of 120,000 to 160,000 cells/ml) of approximately 48 hours
20 followed by and incubation of 2 hours with the MTS/PMS
Reagent is optimal.
In order to establish the accuracy of this assay a Positive
Control consisting of 50 µM Methotrexate should not
decrease the net absorbance to less than 90% of the Negative
25 Control (CCL220 cells are somewhat resistant to
methotrexate) is utilized.
Animal Toxcity Bioassay
Acute toxicity was studied on white mice of both sexes
with weight ranging between 18-26 grams under intraperi30 toneal injection of 2% solution of tested compound in starch
OF-12
(the compound was dissolved in starch slime and injected)
on the basis of 0.1 ml of solution per 10 g of the animal
weight Each dose was tested on the group of 6 animals that
It is seen from the above that (OF-13) is an intermediate
were observed during 14 days period. (This method was
product during the synthesis of (OF-12).
35 approved by the Pharmacology committee of Russian MinCytotoxicity Assay.
The antitumor activity against human colon cancer cells
istry of Health and has been widely used since 1968.)
of the novel compounds (as earlier reported) was realized by
Averaged lethal dose (LD 50 ) of the compound was comthe following procedure which determines the inhibitory
puted using results of experiments on 5-7 groups of animals
effect of test samples on the growth of human colon cancer
using method of Litchfield and Wilkinson. (Belenkii M. L.
cells (ATCC CCL220). The CCL220 cells are grown in 40 "Elements of quantative determination of the pharmacologiRPMI 1640 media+10% Fetal bovine serum+l % Antibiotic/
cal effect," Leningrad, 1963, 71 pages).
Antimycotic for approximately 48 hours at 37° C./5% C0 2
Use of the Invention for Treatment of Human Colon Cancer
in the presence of the test compound.
Due to their low toxicity data, the compounds described
Growth/Non-Growth of the cells (e.g., cell density) is
as useful in this invention can be used effectively in a
determined using Promega's MTS/PMS assay system. MTS
45 pharmaceutical composition comprising a non-toxic effec( 3 - ( 4 , 5 - d i m e t h y 1t h i a z o 1 - 2 - y 1) - 5 - ( 3 tive amount of the referenced compound or mixture thereof
carboxymethoxypheny1)-2-(4-sulfopheny l)-2H-tetrazolium,
and/or in a tautomeric form thereof or a pharmaceutically
inner salt) is an aqueous compound that is reduced to soluble
acceptable salt thereof or pharmaceutically acceptable solformazan by the presence of NADH formed by dehydrogevate
thereof, and a pharmaceutically acceptable carrier
nases present within the CCL220 cells. The absorbance of
the formazan can be measured at 490 nm and is directly 50 thereof.
For administration to man in the curative or prophylactic
proportional to the number of living cells present in the
treatment of human colon cancer in vitro dosages of
culture. PMS (Phenazine Methosulfate) is added an electron
compound(s) and admixtures thereof the invention will
coupling reagent and greatly increases the rate of reduction.
generally be in the range of from 5 to 500 mg daily for an
To facilitate a full understanding of the procedure the
55 average adult patient (70 kg). Thus for a typical adult
following definitions are offered:
patient, individual tablets or capsules contain from 2-500
Test wells-wells containing test sample and Diluted
CCL220 cells
mg of active compound, in a suitable pharmaceutically
Test values-absorbance of test wells
acceptable vehicle or carrier, for administration in single or
Blank wells-wells containing test sample and CCL220
multiple doses, once or several times per day. Dosages for
media (C220-01S); used to obtain background absorbance 60 intraveneous, buccal or sublingual administration will typically be within the range of from 5-1000 mg per single dose
due to test sample
Blank values-absorbance of blank wells
as required. The physician will determine the actual dosing
regimen which will be most suitable for an individual patient
Negative Control-maximal cell growth; results of test
by periodic colonoscope and/or anal blood examination to
samples will be expressed as a percent of the Negative
65 evaluate the tumor inhibitory effect of the compound(s)
Control
administered and it will vary with the age, weight and
Positive Control-known inhibitor of CCL220 cells; used to
validate assay system
response of the particular patient.

~
U-----V
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The maximum human non-toxic one time administration
cancer and also but not as well documented Stage III Rectal
dose for the compound(s) of the invention appears to
Cancer. The benefit for Stage II is still unclear. The increase
100--750 mg.
in 5-year survival is in the range from 50% up to 65% for
For human use, the compounds of the invention can be
Stage III Colon Cancer. The drugs being used are 5-FU
administered alone or jointly, but will generally be admin- 5 (fiuorouracil)+Leucovorin or 5-FU+Levamisol. It should be
mentioned that 5-FU drug has been already used for more
istered in admixture with a pharmaceutical carrier selected
than 30 years.
with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
Toxicity of 5-FU drug in mice is IPN-Mice LD50 230 mg
administered orally, buccally or sublingually, in the form of
kg- 1 . It should be compared with IPN-Mice 1500 mg kg- 1
tablets containing excipients such as starch or lactose, or in 10 toxicity of the claimed drug. Consequently the claimed
capasules or ovules either alone or in admixture with
drugs provide basis for the development of new drugs with
excipients, or in the form of elixirs or suspensions containless side effects and lower toxicity.
ing flavouring or colouring agents. The compounds may also
While the invention has been described, disclosed, illusbe injected parenterally, for example intraveneously,
trated and shown in various terms of certain embodiments or
intramuscularly, subcutaneously or intracoronarily. For 15 modifications which it has presumed in practice, the scope
parenteral administration, they are best used in the form of
of the invention is not intended to be, nor should it be
a sterile aqueous solution which may contain other
deemed to be, limited thereby and such other modifications
substances, for example enough salts or glucose to make the
or embodiments as may be suggested by the teachings herein
solution isotonic with blood.
are particularly reserved especially as they fall within the
The invention thus provides a method for the treatment of 20 breadth and scope of the claims here appended.
colon cancer in a human mammal which comprises adminWe claim:
istering an effective, non-toxic, amount of a compound
1. A mixture suitable for administration to a human being
according to the invention or a tautomeric form thereof
comprising 4-Chloro-4-( 4-ethoxy-pheny 1)-2-(fiuoren-9and/or a pharmaceutically acceptable salt thereof and/or a
ylidene-hydrazono)-but-3-enoic acid methyl ester and 4-(4pharmaceutically acceptable solvate thereof, to a: colon 25 Ethoxy-pheny 1)-2-(N' -fiuoren -9-y lidene-h ydrazino )-2cancer invaded human mammal in need thereof.
hydroxy-4-oxo-butyric acid methyl ester having the
property of anti-tumor activity against colorectal cancer.
ADVANTAGES OF THE INVENTION
2. A method of treating a human having colon cancer
comprising the step of: administering an effective amount of
Surgery is the primary treatment for colon cancer and the
30
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lideneonly treatment that can cure the patient. Adjuvant Chemohydrazono )-but-3-enoic acid methyl ester to said human.
therapy means that you treat with chemotherapy after the
3. A method of treating a human having colon cancer
operation that has removed all visible tumor tissue to kill
comprising the step of: administering an effective amount of
single cancer cells or micro metastatic tumor deposits that
4-( 4-Ethoxy-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2may have spread from the primary tumor before or at the
time of surgery through blood or lymph vessels to diminish 35 hydroxy-4-oxo-butyric acid methyl ester to said human.
4. The method according to claim 3 further comprising
the risk of clinically evident distant metastases. The effect of
administering an effective amount of 4-(4-ethoxy-phenyl)adjuvant chemotherapy after colon cancer has been debated
2-(fiuoren-9-ylidene-hydrazono )-but-3-enoic acid methyl
for many years and many studies have been made, some not
ester.
showing any benefit, but some showing a benefit. There is an
40
increasing number of recent studies and meta analyses
showing a positive effect on Stage III (node positive) colon
* * * * *

